Table of Contents
Chemotherapy Research and Practice
Volume 2012, Article ID 838509, 8 pages
http://dx.doi.org/10.1155/2012/838509
Review Article

Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia

Received 16 December 2011; Accepted 7 March 2012

Academic Editor: Enzo Bonmassar

Copyright © 2012 Linda Mileshkin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Bos, E. R. Fearon, and S. R. Hamilton, “Prevalence of ras gene mutations in human colorectal cancers,” Nature, vol. 327, no. 6120, pp. 293–297, 1987. View at Google Scholar · View at Scopus
  2. J. Tie, L. Lipton, J. Desai et al., “KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer,” Clinical Cancer Research, vol. 17, no. 5, pp. 1122–1130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. E. Baldus, K. L. Schaefer, R. Engers, D. Hartleb, N. H. Stoecklein, and H. E. Gabbert, “Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases,” Clinical Cancer Research, vol. 16, no. 3, pp. 790–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. S. D. Richman, M. T. Seymour, P. Chambers et al., “KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5931–5937, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Y. Douillard, S. Siena, J. Cassidy et al., “Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study,” Journal of Clinical Oncology, vol. 28, no. 31, pp. 4697–4705, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. S. Karapetis, S. Khambata-Ford, D. J. Jonker et al., “K-ras mutations and benefit from cetuximab in advanced colorectal cancer,” The New England Journal of Medicine, vol. 359, no. 17, pp. 1757–1765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. W. de Roock, H. Piessevaux, J. de Schutter et al., “KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab,” Annals of Oncology, vol. 19, no. 3, pp. 508–515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Di Fiore, F. Blanchard, F. Charbonnier et al., “Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1166–1169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Frattini, P. Saletti, E. Romagnani et al., “PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients,” British Journal of Cancer, vol. 97, no. 8, pp. 1139–1145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Lievre, J. B. Bachet, V. Boige et al., “KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 374–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Khambata-Ford, C. R. Garrett, N. J. Meropol et al., “Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3230–3237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Benvenuti, A. Sartore-Bianchi, F. di Nicolantonio et al., “Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies,” Cancer Research, vol. 67, no. 6, pp. 2643–2648, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Baas, L. L. Krens, H. J. Guchelaar, H. Morreau, and H. Gelderblom, “Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review,” Oncologist, vol. 16, no. 9, pp. 1239–1249, 2011. View at Google Scholar
  15. D. Santini, F. Loupakis, B. Vincenzi et al., “High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice,” Oncologist, vol. 13, no. 12, pp. 1270–1275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Knijn, L. J. M. Mekenkamp, M. Klomp et al., “KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients,” British Journal of Cancer, vol. 104, no. 6, pp. 1020–1026, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Jimeno, W. A. Messersmith, F. R. Hirsch, W. A. Franklin, and S. Gail Eckhardt, “KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection,” Journal of Clinical Oncology, vol. 27, no. 7, pp. 1130–1136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Williams, F. Pontén, C. Moberg et al., “A high frequency of sequence alterations is due to formalin fixation of archival specimens,” American Journal of Pathology, vol. 155, no. 5, pp. 1467–1471, 1999. View at Google Scholar · View at Scopus
  19. F. Aubin, S. Gill, R. Burkes et al., “Canadian expert group consensus recommendations: KRAS testing in colorectal cancer,” Current Oncology, vol. 18, no. 4, pp. e180–e184, 2011. View at Google Scholar
  20. A. C. Tsiatis, A. Norris-Kirby, R. G. Rich et al., “Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications,” Journal of Molecular Diagnostics, vol. 12, no. 4, pp. 425–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Santini, S. Galluzzo, L. Gaeta, A. Zoccoli, and E. Riva, “Should oncologists be aware in their clinical practice of KRAS molecular analysis?” Journal of Clinical Oncology, vol. 29, no. 8, pp. e206–e207, 2011. View at Publisher · View at Google Scholar
  22. A. Marchetti and G. Gasparini, “K-ras mutations and cetuximab in colorectal cancer,” The New England Journal of Medicine, vol. 360, no. 8, pp. 833–836, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Molinari, L. Felicioni, M. Buscarino et al., “Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer,” Clinical Cancer Research, vol. 17, no. 14, pp. 4901–4914, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Peeters, T. J. Price, A. Cervantes et al., “Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 28, no. 31, pp. 4706–4713, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. E. van Cutsem, C. H. Köhne, E. Hitre et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1408–1417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Peeters et al., “Evaluation of individual codon 12 and 13 mutant (MT) KRAS alleles as prognostic and predictive biomarkers of response to panitumumab (pmab) in patients with petastatic colorectal cancer (mCRC),” in Proceedings of the European Multidisciplinary Cancer Congress, Stockholm, Sweden, 2011.
  27. W. de Roock, D. J. Jonker, F. di Nicolantonio et al., “Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab,” Journal of the American Medical Association, vol. 304, no. 16, pp. 1812–1820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Jacobs, W. de Roock, H. Piessevaux et al., “Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab,” Journal of Clinical Oncology, vol. 27, no. 30, pp. 5068–5074, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Laurent-Puig, A. Cayre, G. Manceau et al., “Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5924–5930, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Mittmann, H. J. Au, D. Tu et al., “Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial,” Journal of the National Cancer Institute, vol. 101, no. 17, pp. 1182–1192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. P. R. Blank, H. Moch, T. D. Szucs, and M. Schwenkglenks, “KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective,” Clinical Cancer Research, vol. 17, no. 19, pp. 6338–6346, 2011. View at Google Scholar
  32. T. S. Mok, Y. L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. V. L. Keedy, S. Temin, M. R. Somerfield et al., “American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 2121–2127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Ishibe, J. Carlson, S. D. Ramsey, A. Freedman, and S. Schully, “Use of epidermal growth factor receptor mutation analysis in patients with advanced non-small-cell lung cancer to determine erlotinib use as first-line therapy,” PLoS Currents, vol. 3, 2011. View at Publisher · View at Google Scholar
  35. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., “Erlotinib in previously treated non-small-cell lung cancer,” The New England Journal of Medicine, vol. 353, no. 2, pp. 123–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Rosell, T. Moran, C. Queralt et al., “Screening for epidermal growth factor receptor mutations in lung cancer,” The New England Journal of Medicine, vol. 361, no. 10, pp. 958–967, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Mazzoni, V. Rotella, N. Pratesi et al., “From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy,” Tumori, vol. 97, no. 2, pp. 160–165, 2011. View at Google Scholar · View at Scopus
  38. L. L. Waller, A. A. Miller, and W. J. Petty, “Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke,” Lung Cancer, vol. 67, no. 1, pp. 12–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. S. P. D'Angelo, M. C. Pietanza, M. L. Johnson et al., “Incidence of EGFR Exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 2066–2070, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Marchetti, C. Martella, L. Felicioni et al., “EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 857–865, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Shukuya, T. Takahashi, R. Kaira et al., “Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports,” Cancer Science, vol. 102, no. 5, pp. 1032–1037, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Sun, Q. Zhang, H. Luan, Z. Zhan, C. Wang, and B. Sun, “Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice,” Journal of Experimental and Clinical Cancer Research, vol. 30, article 30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. D. A. Eberhard, G. Giaccone, and B. E. Johnson, “Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 983–994, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Rosell, M. A. Molina, C. Costa et al., “Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations,” Clinical Cancer Research, vol. 17, no. 5, pp. 1160–1168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Coudert et al., “Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy,” Annals of Oncology, 2011. View at Google Scholar
  46. S. W. Han, T. Y. Kim, K. J. Yoon et al., “Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation,” Clinical Cancer Research, vol. 12, no. 8, pp. 2528–2544, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. P. A. Bradbury, D. Tu, L. Seymour et al., “Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer,” Journal of the National Cancer Institute, vol. 102, no. 5, pp. 298–306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Brown, A. Boland, A. Bagust et al., “Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer,” Health technology assessment, vol. 14, supplement 2, pp. 71–79, 2010. View at Google Scholar · View at Scopus
  49. G. de Lima Lopes Jr., J. E. Segel, D. S. W. Tan, Y. K. Do, T. Mok, and E. A. Finkelstein, “Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung,” Cancer, 2011. View at Publisher · View at Google Scholar · View at Scopus